Table 3.
Crude and Multivariate analyses of medication use and pneumonia in patients with IBD, overall and by CD or UC
| Medication | IBD Overall (n=23,784) | Crohns disease (n=12,025) | Ulcerative Colitis (n=11,645) | ||||
|---|---|---|---|---|---|---|---|
| Crude OR, 95% CI | Adjusted OR, 95% CI | Crude OR, 95% CI | Adjusted OR, 95% CI | Crude OR, 95% CI | Adjusted OR, 95% CI | ||
| Any use in prior 120 days | |||||||
| Biologic | 2.06 (1.77-2.39) | 1.28 (1.08-1.52) | 1.91 (1.62-2.26) | 1.28 (1.05-1.56) | 2.71 (1.96-3.75) | 1.26 (0.87-1.82) | |
| Thiopurine | 1.51 (1.37-1.67) | 1.04 (0.92-1.17) | 1.41 (1.25-1.61) | 1.02 (0.88-1.18) | 1.71 (1.44-2.03) | 1.06 (0.87-1.82) | |
| Corticosteroid | 5.49 (5.04-5.97) | 3.62 (3.30-3.98) | 5.35 (4.75-6.01) | 3.52 (3.10-4.01) | 5.62 (4.97-6.35) | 3.74 (3.27-4.29) | |
| Calcineurin | 3.19 (2.13-4.79) | 0.51 (0.30-0.88) | 2.91 (1.57-5.37) | 0.59 (0.25-1.38) | 3.43 (2.00-5.90) | 0.49 (0.24-0.97) | |
| PPI | 2.21 (2.04-2.39) | 1.14 (1.03-1.25) | 2.20 (1.97-2.45) | 1.17 (1.03-1.33) | 2.19 (1.95-2.47) | 1.10 (0.95-1.27) | |
* ** Biologic defined as infliximab, adalimumab, or certolizumab pegol, thiopurine defined as mercaptopurine or azathioprine
5-ASA defined as mesalamine, olsalazine, balsalazide, sulfasalazine, calcineurin defined as tacrolimus or cyclosporine
***Conditional logistic regression models adjusted for health care utilization, comorbitities, 5-ASA, biologic, thiopurine, corticosteroid, PPI medication use as appropriate
Source: IMS Health, LifeLink™ Health Plan Claims Database, From 1997 to 2009